Study guide

4.2 Renal, Hepatic, and Endocrine Trajectories

Certified Hospice and Palliative Nurse CHPN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Fees, Windows, and Retakes 1.3 Scoring, Test-Day Rules, and Remote Proctoring 1.4 Recertification: HPAR and the Situational Judgment Exercise

2 Chapter 2: Assessment, Goals, and Care Planning

2.1 Goals of Care and Shared Decision Making 2.2 Interdisciplinary Care Planning and Ongoing Evaluation 2.3 Prognostic and Functional Assessment Tools 2.4 Levels of Care and Care-Setting Transitions

3 Chapter 3: Life-Limiting Disease Progression I

3.1 Cancer, Hematologic, and Paraneoplastic Complications 3.2 Heart Failure and Cardiac Disease Progression 3.3 Pulmonary Disease Progression 3.4 Neurologic Disease Progression

4 Chapter 4: Disease Progression II and Imminent Death

4.1 Dementia, Frailty, and Feeding Decisions 4.2 Renal, Hepatic, and Endocrine Trajectories 4.3 Indicators of Imminent Death

5 Chapter 5: Pain Assessment

5.1 Pain Types, Etiology, and Syndromes 5.2 Verbal and Nonverbal Pain Assessment and Scales 5.3 Factors That Influence the Pain Experience

6 Chapter 6: Pharmacologic Pain Management

6.1 Opioid and Non-Opioid Analgesics by Pain Type and Severity 6.2 Adjuvant Analgesics 6.3 Titration, Baseline Dosing, and Breakthrough Pain 6.4 Equianalgesic Conversion and Route Changes

7 Chapter 7: Nonpharmacologic Pain and Opioid Safety

7.1 Nonpharmacologic Pain Interventions 7.2 Complementary and Integrative Pain Therapies 7.3 Opioid Adverse Effects, Neurotoxicity, and Rotation

8 Chapter 8: Neurological, Cardiovascular, and Respiratory Symptoms

8.1 Neurological Symptoms 8.2 Delirium and Terminal Restlessness 8.3 Cardiovascular Symptoms 8.4 Respiratory Symptoms: Dyspnea, Cough, and Secretions

9 Chapter 9: Gastrointestinal, Genitourinary, and Musculoskeletal Symptoms

9.1 Gastrointestinal Symptoms 9.2 Genitourinary Symptoms 9.3 Musculoskeletal Symptoms

10 Chapter 10: Skin, Metabolic, Hematologic, and Psychospiritual Symptoms

10.1 Skin and Mucous Membrane Symptoms 10.2 Nutritional and Metabolic Symptoms 10.3 Immune and Hematologic Symptoms 10.4 Psychosocial, Emotional, and Spiritual Symptom Burden

11 Chapter 11: Advance Care Planning, Benefits, and Safety

11.1 Advance Care Planning and Life-Sustaining Therapies 11.2 Hospice and Palliative Benefits under Medicare, Medicaid, and Private Insurance 11.3 Patient Safety: Environmental, Physical, and Socioemotional

12 Chapter 12: Communication, Culture, and Psychosocial Support

12.1 Communication Techniques, Barriers, and Family Meetings 12.2 Cultural Humility and Spiritual Needs 12.3 Psychosocial Needs and IDG Participation

13 Chapter 13: Caregiver Education and Medication Management

13.1 Medication Management and Controlled Substances 13.2 Caregiver and Family Self-Care 13.3 Teaching End-Stage Disease, Pain, and Symptom Plans 13.4 Caregiver Skills, DME, Supplies, and Services

14 Chapter 14: Grief, Death, and End-of-Life Ethics

14.1 Grief, Loss, and Bereavement 14.2 Support at the Time of Death and Post-Mortem Care 14.3 Ethical Issues Related to End of Life

15 Chapter 15: Medicare Hospice Compliance and National Standards

15.1 Medicare Hospice Benefit and Conditions of Participation 15.2 Hospice Eligibility, Admission, and Recertification 15.3 National Hospice and Palliative Care Standards 15.4 National Consensus Project Clinical Practice Guidelines

16 Chapter 16: Legal, Professional Practice, Quality, and Policy

16.1 Legal Regulations: CMS, HIPAA, and OSHA 16.2 Professional Boundaries and Ethics 16.3 QAPI, Self-Care, and Precepting 16.4 Policy, Delivery, and Reimbursement Trends

4.2 Renal, Hepatic, and Endocrine Trajectories

Key Takeaways Explain This Topic AI

After dialysis is stopped, death often occurs in days to about two weeks, with wide individual variation; do not promise a clock time.

Uremic dying commonly includes pruritus, myoclonus, volume overload, nausea, and encephalopathy; treat the symptoms, not the creatinine number.

Decompensated cirrhosis clusters ascites, hepatic encephalopathy, variceal bleeding, and spontaneous bacterial peritonitis; hepatorenal syndrome signals very limited reversibility.

In hospice diabetes, liberalize glucose goals and reduce or hold insulin when the person is not eating so hypoglycemia does not become the terminal event.

Morphine-6-glucuronide accumulates in renal failure; hydromorphone, fentanyl, or methadone are generally preferred with caution rather than unadjusted morphine.

Last updated: August 2026

4.2 Renal, Hepatic, and Endocrine Trajectories

Organ-failure clocks differ from dementia's years-long fade and from cancer's months. End-stage renal disease (ESRD) after the last dialysis session, decompensated cirrhosis, and diabetes as a hospice comorbidity are high-yield Domain 1.C remainder topics. The CHPN RN anticipates symptom clusters, medication accumulation, and family questions about "how long after we stop." +-----------------------------------------------------------------------------------------+

  • | ORGAN-FAILURE TRAJECTORIES THE CHPN MUST SEPARATE |
  • | |
  • | ESRD / last dialysis Cirrhosis / hepatorenal Diabetes as comorbidity |
  • | - Days to ~2 weeks - Bleeds, SBP, coma - Liberalize glucose |
  • | (variable) - Hepatorenal = poor - Avoid hypoglycemia |
  • | - Uremic symptom set reversibility from leftover insulin |
  • +-----------------------------------------------------------------------------------------+
  • ESRD: stopping dialysis

Stopping hemodialysis or peritoneal dialysis is a valid, often planned decision when the burden of transport, hemodynamic instability, access pain, or dwindling quality of life outweighs the benefit of extra days. It is not suicide, and it is not the nurse's job to talk a capacitated adult into one more session "for the family."

Timing of death after the last dialysis is typically days to about two weeks , with substantial variation. Residual kidney function, remaining urine output, volume status, and comorbid heart disease move the window. An anuric person with pulmonary edema may die within a short interval; a person with leftover clearance may live longer than families were told. Teach a range , not a date. Recertification and visit frequency should follow the actual decline, not a stopwatch started at the last treatment.

Uremic symptom cluster

As nitrogenous wastes and fluid accumulate, expect:

Symptom Why it happens Hospice nursing implication

Pruritus Uremic toxins, calcium-phosphate imbalance, dry skin Moisturize, keep nails short, consider IDT antipruritic plan; scratching is not "noncompliance"

Myoclonus / twitching Uremia plus opioid metabolite neuroexcitation Distinguish from seizures; review opioid choice and dose

Volume overload No dialysis ultrafiltration Dyspnea, edema; positioning, opioids for air hunger, possible comfort paracentesis if ascites coexists

Nausea, metallic taste, anorexia Uremic gastroenteropathy Haloperidol or other antiemetics per protocol; do not force meals

Encephalopathy / asterixis Uremic neurotoxicity Safety, delirium care, family teaching that confusion is the disease

Restless legs, cramps Uremia, shifts in electrolytes Nonpharmacologic measures plus IDT medication review

Uremic frost is rare in modern practice; do not wait for it. Platelet dysfunction can increase bruising. Pericarditis is possible but less often the CHPN's first recognition task than pruritus, twitching, and drowning-in-fluid dyspnea.

Worked family conversation: After the last hemodialysis on Monday, a daughter asks whether death will come "tonight." Accurate CHPN language: many people die within days to about two weeks, some sooner if they have no urine and severe volume overload, some later if residual function remains. Hospice will treat itch, twitching, and breathlessness. Calling a precise hour is not honest and is not required.

Hepatorenal syndrome and decompensated cirrhosis

Hepatorenal syndrome is kidney failure driven by advanced liver disease without a primary intrinsic renal diagnosis that will reverse with fluids alone. Splanchnic vasodilation and renal vasoconstriction produce oliguria and rising creatinine in a yellow, ascitic patient. In hospice it usually means the dual-organ clock is short. Do not frame large-volume albumin-plus-vasoconstrictor protocols as a standard home-hospice expectation; the exam cares that you recognize the combination as poorly reversible and intensely symptomatic (volume, encephalopathy, itch, pain from tense ascites).

Decompensated cirrhosis announces itself in a cluster the CHPN should list without hesitation:

Ascites. Tense fluid causes pain, early satiety, and dyspnea. Comfort paracentesis can be palliative. Spironolactone and loop diuretics help some patients until blood pressure and kidneys collapse; they are not mandatory at the end.

Hepatic encephalopathy. Ammonia and other toxins produce day-night reversal, asterixis, then coma. Lactulose and rifaximin are common disease-directed remnants; in active dying the goal is comfort, not a normal ammonia. Avoid unnecessary benzodiazepines that deepen coma—except when they are the chosen palliation for terminal agitation, with eyes open about sedation.

Variceal bleeding. A sudden massive hematemesis can be the terminal event. Dark towels, a calm RN, octreotide or other bleed-pathway orders if the program uses them, and family presence matter more than transfer for banding in a person already on a hospice path.

Spontaneous bacterial peritonitis (SBP). Infected ascites presents as fever, abdominal pain, or simply worse encephalopathy. It may be treated once; recurrent SBP in a dying patient is often a signal to shift fully to comfort, not an infinite antibiotic loop.

Jaundice, muscle wasting, and spider angiomas support the diagnosis but do not time death by themselves. Coagulopathy increases bruising and GI bleeding risk; intramuscular injections are a poor default.

Endocrine trajectories: diabetes first, thyroid rarely

Diabetes in hospice is usually a comorbidity , not the primary terminal diagnosis. Tight A1C targets that made sense for a 20-year prevention horizon become harmful when the person is not eating. Liberalize glucose goals. The enemy is hypoglycemia from continued home insulin or sulfonylureas after intake collapses. Hold or sharply reduce insulin when meals stop; many programs treat only symptomatic hyperglycemia or very high values that cause thirst, osmotic diuresis, or distress. Sliding-scale insulin as a "just in case" ritual often causes more needle pain than benefit. Metformin is commonly already stopped in organ failure because of lactic acidosis risk. Do not invent a single national milligram-per-deciliter cutoff; teach the principle: no hypoglycemia, no symptomatic hyperglycemia, no leftover full-dose insulin in a person who has stopped eating.

Myxedema coma (severe hypothyroidism: hypothermia, bradycardia, ileus, coma) and thyroid storm are rare hospice primary trajectories. Mention them so you do not mislabel every hypothermic, bradycardic death as "just dying" without a history, and so you do not chase thyroid laboratories in an actively dying patient whose thyroid disease is long-standing and irrelevant. They are not the everyday CHPN clock.

Medication accumulation in renal and hepatic failure

Kidneys and liver are the two clearance organs that turn ordinary analgesic orders into toxicity.

Morphine is glucuronidated to morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G). M6G is an active opioid that accumulates when glomerular filtration falls , producing delayed, prolonged sedation and respiratory depression. M3G contributes to neuroexcitation (myoclonus, allodynia, agitation). In ESRD and advanced chronic kidney disease, do not treat unadjusted morphine as first-line . Prefer hydromorphone , fentanyl , or methadone in context, all with caution:

  • Opioid Renal failure teaching Hepatic failure teaching
  • Morphine M6G/M3G accumulate; generally avoid as routine ESRD opioid Reduced clearance; start low

Hydromorphone Often preferred over morphine; hydromorphone-3-glucuronide can still cause myoclonus—use lower doses and longer intervals Still use low and slow

Fentanyl No M6G-type active glucuronide story; transdermal patches are unreliable in cachexia and in rapidly changing dying Unpredictable; avoid naive patch starts

Methadone Hepatic metabolism, useful in renal failure in experienced hands Liver metabolized; long, variable half-life; QT and specialist caution

Hepatic failure also prolongs many benzodiazepines and increases bioavailability of high first-pass drugs. The CHPN's reflex is start low, extend intervals, watch myoclonus and sedation , and ask the IDT pharmacist or medical director before copying an old morphine PCA order onto an anuric patient.

CHPN RN role: name uremic and cirrhotic clusters, teach a variable post-dialysis timeline, liberalize diabetes, and catch morphine in renal failure before the family wonders why twitching started after "just a little extra pain medicine."

Loading diagram... Renal, hepatic, and endocrine clocks in hospice

Illustrative teaching bands: timing of death after last dialysis (not a prediction for one patient)